^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The panel has included the combination of venetoclax + ibrutinib as an option with a category 2B recommendation based on the results of a phase II study that showed improved outcomes in patients with MCL...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    LBA-2 Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

    Published date:
    11/02/2023
    Excerpt:
    The Ibr+Ven combination demonstrated a statistically significant improvement in PFS compared with Ibr+Pbo in pts with R/R MCL; CR rates and TTNT were also significantly improved with Ibr+Ven….
    Trial ID:
    SYMPATICO